Latest News & Features
Pharma
Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen. 8 October 2026
Pharma
Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations. 8 October 2026
Careers
The firm has snapped up IP partners from Sheridan Ross as it ramps up its presence in Denver and targets growing demand from life sciences and technology clients. 8 October 2026
In-house counsel
With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact. 7 October 2026
Pharma
Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight. 6 October 2026
Careers
The new partner advises technology and life sciences companies in Section 337 investigations and related patent disputes, drawing on extensive private practice and government experience. 6 October 2026
Regulation & Industry
Tapio Blanc, chief trademark officer at Roche, explains why fighting fakes can be a matter of life and death, and how AI, online platforms, and ‘mousetrap buys’ are affecting brand protection. 5 October 2026
Careers
Based in Munich, Germany, the new principal—who brings SEP licensing and trade secret expertise—will help grow the firm’s cross-border capabilities across Europe. 5 October 2026
In-house counsel
AI is helping legal and IP teams handle more work without adding headcount, but in-house counsel at LSPN Europe warn that knowing when not to rely on the technology is just as important as knowing how to use it. 2 October 2026
In-house counsel
With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters. 1 October 2026